↓ Skip to main content

Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma

Overview of attention for article published in Molecular Therapy, May 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news
1 news outlet
blogs
1 blog
twitter
11 X users
patent
23 patents

Citations

dimensions_citation
87 Dimensions

Readers on

mendeley
140 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma
Published in
Molecular Therapy, May 2015
DOI 10.1038/mt.2015.71
Pubmed ID
Authors

Joal D Beane, Gary Lee, Zhili Zheng, Matthew Mendel, Daniel Abate-Daga, Mini Bharathan, Mary Black, Nimisha Gandhi, Zhiya Yu, Smita Chandran, Martin Giedlin, Dale Ando, Jeff Miller, David Paschon, Dmitry Guschin, Edward J Rebar, Andreas Reik, Michael C Holmes, Philip D Gregory, Nicholas P Restifo, Steven A Rosenberg, Richard A Morgan, Steven A Feldman

Abstract

Programmed cell death-1 (PD-1) is expressed on activated T cells and represents an attractive target for gene-editing of tumor targeted T cells prior to adoptive cell transfer (ACT). We used zinc finger nucleases (ZFNs) directed against the gene encoding human PD-1 (PDCD-1) to gene-edit melanoma TIL. We show that our clinical scale TIL production process yielded efficient modification of the PD-1 gene locus, with an average modification frequency of 74.8% (n=3, range 69.9 - 84.1%) of the alleles in a bulk TIL population, which resulted in a 76% reduction in PD-1 surface-expression. Forty to 48% of PD-1 gene-edited cells had biallelic PD-1 modification. Importantly, the PD-1 gene-edited TIL product showed improved in vitro effector function and a significantly increased polyfunctional cytokine profile (TNFα, GM-CSF and IFNγ) compared to unmodified TIL in two of the three donors tested. In addition, all donor cells displayed an effector memory phenotype and expanded approximately 500 - 2000 fold in vitro. Thus, further study to determine the efficiency and safety of adoptive cell transfer using PD-1 gene-edited TIL for the treatment of metastatic melanoma is warranted.Molecular Therapy (2015); doi:10.1038/mt.2015.71.

X Demographics

X Demographics

The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 140 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 1%
Unknown 138 99%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 31 22%
Researcher 30 21%
Student > Master 14 10%
Student > Bachelor 11 8%
Student > Doctoral Student 8 6%
Other 16 11%
Unknown 30 21%
Readers by discipline Count As %
Agricultural and Biological Sciences 31 22%
Biochemistry, Genetics and Molecular Biology 23 16%
Immunology and Microbiology 19 14%
Medicine and Dentistry 17 12%
Pharmacology, Toxicology and Pharmaceutical Science 6 4%
Other 15 11%
Unknown 29 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 30. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 February 2024.
All research outputs
#1,322,979
of 25,373,627 outputs
Outputs from Molecular Therapy
#300
of 4,915 outputs
Outputs of similar age
#16,292
of 279,206 outputs
Outputs of similar age from Molecular Therapy
#7
of 95 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,915 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.2. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,206 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 95 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.